Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend.
Academic rigour, journalistic flair
Articles on Biosimilars
Displaying all articles
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here’s where they come from and how they work.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
Job Board
-
Associate Professor, Occupational Therapy
-
GRAINS RESEARCH AND DEVELOPMENT CORPORATION CHAIRPERSON
-
Technical Skills Laboratory Officer
-
Faculty of Law - Academic Appointment Opportunities
-
Audience Development Coordinator (fixed-term maternity cover)
Top contributors
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Associate Professor in Public Health, La Trobe University
-
Honarary Associate Professor; economics of patents, copyright and other "IP", Australian National University
-
Research Fellow, NHMRC Centre for Research Excellence in the Social Determinants of Health Equity, School of Regulation and Global Governance, Australian National University
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Doctoral Student in Biochemistry, University of Washington
